# US 2021/0260037 A1 · Melanocortin agents for use in the therapeutic treatment of melanoma, tumors of the gastrointestinal tract, and thyroid carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260037 A1
- Document ID: US20210260037A1
- Status: Published application
- Kind: A1
- Application number: 17/253,883
- Filed: 2019-06-14
- Published: 2021-08-26
- Earliest claimed: 2018-06-18
- Assignees: Universita' Di Pisa; Universita' Degli Studi Di Modena E Reggio Emilia
- Applicants: Universita' Di Pisa; Universita' Degli Studi Di Modena E Reggio Emilia
- Inventors: Guido BOCCI; Teresa DI DESIDERO; Daniela GIULIANI; Salvatore GUARINI; Paola ORLANDI; Alessandra OTTANI; Carla Maria Francesca PARDINI; Francesca VAGLINI
- Web page: https://patentgrep.com/patent/US20210260037A1

## CPC

- A61K 31/4164: 1,3-Diazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of therapeutic treatment of a tumor pathology including melanoma, tumors of the gastrointestinal tract, and/or thyroid carcinoma by administering to a subject in need thereof melanocortin receptor-4 (MC4R) antagonists is provided. The melanocortin receptor-4 antagonists are suitable in a targeted anti-tumor treatment, and particularly in an adjuvant therapy or in a therapy affecting onset and/or progression of tumor metastasis. A pharmaceutical composition including a melanocortin receptor-4 (MC4R) antagonist in a pharmaceutically acceptable vehicle, and in combination with optional adjuvants, stabilizers and/or preservatives, is also provided.

## Claims

### Claim 1

A method of therapeutic treatment of a tumor pathology selected from the group consisting of melanoma, tumors of the gastrointestinal tract, and thyroid carcinoma, said therapeutic treatment comprising administering to a subject in need thereof a melanocortin receptor-4 antagonist having formula (I)
or pharmaceutically acceptable salts and esters thereof, wherein
R and R2 are independently a halogen atom; and
R1 is a C1-C4 alkyl group.

### Claim 2 (depends on 1)

The method of claim 1, wherein R is a bromine atom and/or R2 is a fluorine atom.

### Claim 3 (depends on 1)

The method of claim 1, wherein R1 is a methyl group.

### Claim 4 (depends on 1)

The method of claim 1, wherein the melanocortin receptor-4 antagonist has formula (II)

### Claim 5 (depends on 1)

The method of claim 1, wherein the therapeutic treatment is an adjuvant therapy or a therapy affecting onset and/or progression of metastasis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutic treatment is also suitable for controlling neoplastic cachexia.

### Claim 7 (depends on 1)

The method of claim 1, wherein the therapeutic treatment further comprises administering one or more cytotoxic and/or cytostatic agents selected from the group consisting of BRAF inhibitors, MEK inhibitors, tyrosine kinase inhibitors, and combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the melanocortin receptor-4 antagonist is administered as a pharmaceutical composition, said pharmaceutical composition further comprising at least one pharmaceutically acceptable vehicle, excipient, and/or diluent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition is in a pharmaceutical form suitable for being administered via topical, oral, sublingual, buccal, rectal, subcutaneous, intradermic, transcutaneous, intramuscular, intranasal, inhalation, intravenous, intraarterial, intraperitoneal, intrathecal, intracerebroventricular route or via hyperthermic isolated limb perfusion.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pharmaceutical composition is in a pharmaceutical form suitable for being administered to a patient at a daily dose of the melanocortin receptor-4 antagonist comprised between 1 and 100 mg/kg of body weight of the patient.

### Claim 11 (depends on 10)

The method of claim 10, wherein the daily dose of the melanocortin receptor-4 antagonist is of at least 50 mg/kg of body weight of the patient.

### Claim 12 (depends on 11)

The method of claim 11, wherein the daily dose of the melanocortin receptor-4 antagonist is of at least 25 mg/kg of body weight of the patient.
